Kang Jin Han, Lee Soo Young, Kim Jong Hyun, Hur Jae Kyun, Lee Kyung Yil
Department of Pediatrics, The Catholic University of Korea, Seoul, Korea.
Jpn J Antibiot. 2010 Feb;63(1):11-7.
The antibacterial susceptibility to frequently prescribed antibiotics of Streptococcus pneumoniae isolated from the pediatric patients with acute respiratory infectious diseases was investigated in a study of three medical institutions in Korea. Total 143 clinical isolates of S. pneumoniae were available for susceptibility tests between May 2003 and July 2007. Antimicrobial susceptibility data for S. pneumoniae were analyzed by using agents of amoxicillin, cefaclor, cefuroxime, cefdinir, and cefditoren as the test antibiotics. The prevalence of each resistance class, penicillin-resistant S. pneumoniae (PRSP) were high with the proportion of MIC range (susceptible = 8.4%, intermediate resistance = 18.2%, resistance = 73.4%). MIC90 and susceptible (S) rate of antimicrobial agents to the strains tested were amoxicillin (MIC90 = 4 microg/ml, S = 76.2%), cefaclor (MIC90 = 128 microg/ml, S=8.4%), cefuroxime (MIC90 = 16 microg/ml, S = 24.5%), cefdinir (MIC90 = 16 microg/ml, S = 21.8%), and cefditoren (MIC90 = 0.5 microg/ml, S=90.2%) respectively. Against clinical isolates including PRSP, cefditoren demonstrated the strongest antibacterial activity intrinsically among the antibiotics tested. Conclusively, the antimicrobial activity of cefditoren to S. pneumoniae strains isolated from pediatric patients with acute respiratory infection is very high. In South Korea, where the antibiotic resistance ofS. pneumoniae is issued, cefditoren is expected to be used as a primary or secondary antibiotic. Moreover, cefditoren may serve as a useful option for secondary antibiotics after failure of amoxicillin treatment, which is most primarily used for acute respiratory S. pneumoniae infection in children.
在韩国的三家医疗机构开展的一项研究中,对从患有急性呼吸道传染病的儿科患者中分离出的肺炎链球菌,进行了其对常用抗生素的药敏试验。2003年5月至2007年7月期间,共有143株肺炎链球菌临床分离株可用于药敏试验。采用阿莫西林、头孢克洛、头孢呋辛、头孢地尼和头孢妥仑作为测试抗生素,分析了肺炎链球菌的药敏数据。各耐药类别中,青霉素耐药肺炎链球菌(PRSP)的患病率很高,其MIC范围比例为(敏感=8.4%,中介耐药=18.2%,耐药=73.4%)。受试菌株对抗菌药物的MIC90和敏感(S)率分别为:阿莫西林(MIC90 = 4微克/毫升,S = 76.2%)、头孢克洛(MIC90 = 128微克/毫升,S = 8.4%)、头孢呋辛(MIC90 = 16微克/毫升,S = 24.5%)、头孢地尼(MIC90 = 16微克/毫升,S = 21.8%)和头孢妥仑(MIC90 = 0.5微克/毫升,S = 90.2%)。在受试抗生素中,头孢妥仑对包括PRSP在内的临床分离株表现出最强的固有抗菌活性。总之,头孢妥仑对从患有急性呼吸道感染的儿科患者中分离出的肺炎链球菌菌株的抗菌活性非常高。在肺炎链球菌出现抗生素耐药性的韩国,头孢妥仑有望用作一线或二线抗生素。此外,在阿莫西林治疗失败后,头孢妥仑可能作为二线抗生素的一个有用选择,阿莫西林是儿童急性呼吸道肺炎链球菌感染最主要使用的药物。